Loading
A phase 3 trial of Apalutamide, Abiraterone acetate and Prednisone in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT02257736 by Aragon Pharmaceuticals, Inc., with 982 participants enrolled, started 2014-11-26 and due to reach its primary completion in 2018-03-19. Interventions recorded: Apalutamide, Abiraterone acetate, Prednisone and Placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
982 enrolled.
95% CI 13.86 to 19.32; Figures from the ClinicalTrials.gov results section (first posted 2021-08-16), not from a publication · 95% CI 19.71 to 27.50
Source95% CI 31.24 to 38.28; Figures from the ClinicalTrials.gov results section (first posted 2021-08-16), not from a publication · 95% CI 32.76 to 38.77
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Radiographic Progression-free Survival (rPFS)primary | Placebo+ Abiraterone Acetate - Prednisolone | 490 | 16.59 months | - | - | link |
| Apalutamide + Abiraterone Acetate - Prednisolone | 492 | 23.98 months | ||||
| Overall Survival (OS) | Placebo+ Abiraterone Acetate - Prednisolone | 490 | 33.71 months | - | - | link |
| Apalutamide + Abiraterone Acetate - Prednisolone | 492 | 36.17 months |
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Apalutamide, Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.